
CHRS
Healthcare · Biotechnology · $81.2M market cap
$0.5249-0.01 (-2.5%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +6.7% over 90 days · 30-day revisions 1 up, 1 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 9, 2026 | After the close | -0.22 | -0.25 | -13.6% |
| Aug 5, 2026 | After the close | -0.16 | -0.22 | -37.5% |
| May 11, 2026 | After the close | -0.26 | -0.25 | +3.8% |
| Mar 17, 2026 | Time not confirmed | -0.34 | -0.34 | -0.5% |
| Nov 6, 2025 | After the close | -0.29 | -0.33 | -13.8% |
| Aug 7, 2025 | After the close | -0.25 | -0.39 | -56.0% |
| May 12, 2025 | After the close | -0.22 | -0.35 | -59.1% |
| Mar 11, 2025 | Before the open | -0.13 | -0.28 | -114.6% |
| Nov 6, 2024 | After the close | -0.11 | -0.01 | +90.9% |
| Aug 8, 2024 | After the close | -0.26 | -0.14 | +46.2% |
| May 9, 2024 | After the close | -0.21 | -0.32 | -52.4% |
| Mar 13, 2024 | After the close | -0.12 | -0.62 | -416.7% |
| Nov 6, 2023 | After the close | -0.24 |
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1)…
| -0.27 |
| -12.5% |
| Aug 2, 2023 | After the close | -0.44 | -0.38 | +13.6% |
| May 8, 2023 | After the close | -0.47 | -0.80 | -70.2% |
| Mar 6, 2023 | After the close | -0.84 | -0.60 | +28.6% |
| Nov 8, 2022 | After the close | -0.61 | -0.96 | -57.4% |
| Aug 4, 2022 | After the close | -0.73 | -0.47 | +35.6% |
| May 5, 2022 | After the close | -0.65 | -1.00 | -53.8% |
| Feb 17, 2022 | After the close | -0.54 | -0.60 | -11.1% |
| Nov 8, 2021 | After the close | -0.29 | -0.49 | -69.0% |
| Aug 5, 2021 | After the close | -0.15 | -0.40 | -166.7% |
| May 6, 2021 | After the close | 0.11 | -0.23 | -309.1% |
| Feb 24, 2021 | After the close | 0.23 | 0.12 | -47.8% |
| Nov 5, 2020 | After the close | 0.34 | 0.33 | -2.9% |
| Aug 6, 2020 | After the close | 0.29 | 0.70 | +141.4% |
| May 7, 2020 | After the close | 0.48 | 0.48 | 0.0% |
| Feb 27, 2020 | After the close | 0.72 | 0.56 | -22.2% |
| Nov 6, 2019 | After the close | 0.42 | 0.63 | +50.0% |
| Aug 1, 2019 | After the close | -0.04 | 0.32 | +900.0% |
| May 9, 2019 | After the close | -0.46 | -0.29 | +37.0% |
| Feb 28, 2019 | After the close | -0.86 | -0.92 | -7.0% |
| Nov 8, 2018 | After the close | -0.79 | -0.87 | -10.1% |
| Aug 8, 2018 | After the close | -0.65 | -0.68 | -4.6% |
| May 10, 2018 | After the close | -0.70 | -0.74 | -5.7% |
| Mar 8, 2018 | After the close | -0.81 | -0.84 | -3.7% |